Prestige Consumer Healthcare Inc. $PBH Shares Bought by Truist Financial Corp

Truist Financial Corp lifted its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 41.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,906 shares of the company’s stock after purchasing an additional 1,721 shares during the quarter. Truist Financial Corp’s holdings in Prestige Consumer Healthcare were worth $472,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in PBH. Cerity Partners LLC boosted its position in Prestige Consumer Healthcare by 3.7% during the first quarter. Cerity Partners LLC now owns 3,666 shares of the company’s stock worth $315,000 after purchasing an additional 132 shares in the last quarter. UMB Bank n.a. increased its holdings in Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock valued at $26,000 after acquiring an additional 144 shares in the last quarter. KBC Group NV boosted its stake in shares of Prestige Consumer Healthcare by 7.4% during the 1st quarter. KBC Group NV now owns 2,199 shares of the company’s stock worth $189,000 after purchasing an additional 151 shares during the last quarter. Xponance Inc. raised its holdings in Prestige Consumer Healthcare by 5.5% in the 1st quarter. Xponance Inc. now owns 3,766 shares of the company’s stock valued at $324,000 after acquiring an additional 196 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. lifted its holdings in shares of Prestige Consumer Healthcare by 2.3% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 9,105 shares of the company’s stock worth $783,000 after acquiring an additional 203 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective on the stock in a report on Wednesday, September 24th. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Finally, Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Thursday, September 4th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $94.80.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $61.78 on Friday. Prestige Consumer Healthcare Inc. has a 52-week low of $60.15 and a 52-week high of $90.04. The firm has a market capitalization of $3.04 billion, a PE ratio of 14.50, a P/E/G ratio of 1.93 and a beta of 0.44. The firm has a 50-day moving average price of $64.38 and a 200 day moving average price of $75.54. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company’s quarterly revenue was down 6.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.